Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Income from Continuing Operations (2016 - 2025)

Avalo Therapeutics' Income from Continuing Operations history spans 12 years, with the latest figure at 13720000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 61.18% year-over-year to 13720000.0; the TTM value through Dec 2025 reached 78259000.0, down 122.78%, while the annual FY2025 figure was 78259000.0, 122.78% down from the prior year.
  • Income from Continuing Operations reached 13720000.0 in Q4 2025 per AVTX's latest filing, up from 30625000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 98463000.0 in Q2 2024 to a low of 121290000.0 in Q1 2024.
  • Average Income from Continuing Operations over 5 years is 13546550.0, with a median of 13434500.0 recorded in 2025.
  • The largest YoY upside for Income from Continuing Operations was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 19131000.0 in 2021, then skyrocketed by 48.71% to 9812000.0 in 2022, then rose by 16.75% to 8168000.0 in 2023, then crashed by 332.65% to 35339000.0 in 2024, then skyrocketed by 61.18% to 13720000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Income from Continuing Operations are 13720000.0 (Q4 2025), 30625000.0 (Q3 2025), and 20765000.0 (Q2 2025).